Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia

Bronx VA Medical Center

Status and phase

Unknown

Phase 4

Conditions

Hypercholesterolemia

Treatments

Drug: Rosuvastatin

Drug: Ezetimibe

Study type

Interventional

Funder types

Other U.S. Federal agency

Identifiers

NCT00972829

BAR-09-07

Details and patient eligibility

About

Recently, research studies have shown that patients who have had trouble taking statins every day, are able to take statins if they take them only once or twice a week. The investigators are doing a research study which involves switching people who are taking ezetimibe to the statin Crestor once or twice a week and to see how ell Crestor lowers cholesterol and if it is tolerated.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with a history of intolerance to statins
Patients currently receiving ezetimibe
Patients willing and able to provide signed informed consent

Exclusion criteria

Patients receiving a statin (Lipitor, Crestor, Lescol, Simvastatin, or Pravachol)
Stroke, TIA, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass surgery, or major surgery within 3 months
Cancer undergoing active treatment
Creatinine clearance < 40 ml/minute
Active liver disease or persistent elevation of SGOT or SGPT > 2 times the upper limit of normal level
Participation in any clinical study within the last 30 days
Drug addition or alcohol abuse within the past 6 months
Use of cyclosporine within the last 3 months
Use of gemfibrozil within the last month
Patients unwilling or unable to provide informed consent
Patients with poor compliance
Women of childbearing potential
History of rhabdomyolysis due to statins